The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment

Abstract Background Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD). Methods For the purpose of identifying butyrat...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanchao Luan, Chao Liang, Qingsong Han, Xueqin Zhou, Na Yang, li Zhao
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-024-13409-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594651877474304
author Yanchao Luan
Chao Liang
Qingsong Han
Xueqin Zhou
Na Yang
li Zhao
author_facet Yanchao Luan
Chao Liang
Qingsong Han
Xueqin Zhou
Na Yang
li Zhao
author_sort Yanchao Luan
collection DOAJ
description Abstract Background Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD). Methods For the purpose of identifying butyrate metabolism-related differentially expressed genes (BMR-DEGs) in the TCGA-LUAD dataset, we introduced transcriptome data. This was followed by the implementation of the univariate Cox and LASSO analyses in order to construct a LUAD gene signature. We performed a comprehensive analysis of gene function enrichment between the two populations at risk, thoroughly examined their immune microenvironment characteristics, and assessed the effectiveness of immunotherapy. Finally, the function of CDKN3 in LUAD was verified by in vitro experiments. Results Through a comprehensive analysis of the TCGA-LUAD dataset, 51 significant BMR-DEGs were confirmed. Subsequently, five characteristic genes, CPS1, ABCC2, CDKN3, SLC2A1, and IGFBP1 were identified to create prognostic features for butyrate metabolism related outcomes in LUAD. Cox regression analysis determined that the pathological T stage, tumor stage, and RiskScore could serve as independent prognostic indicators. Analysis of the abundance of 22 immune infiltrating cells revealed that 15 immune cell types exhibited substantial differences and were strongly associated with risk ratings and prognosis. An important correlation exists between risk ratings and immunological checkpoints, which can be utilized to forecast the efficacy of treatment. In the high-risk group, there was an upregulation of the expression of PD-L2, PD-L1, and PD-1. Additionally, the risk score showed a positive correlation with TIDE and Exclusion score, while showing a negative correlation with Dysfunction score. Furthermore, the IC50 values for cisplatin, paclitaxel, and docetaxel were notably elevated in the high-risk group, indicating that these medications could potentially provide therapeutic advantages for this particular group. Finally, we determined that knockdown CDKN3 inhibited the proliferation and metastasis of LUAD cells. Conclusion We identify and validate a novel BMR-related prognostic signature comprising 5 DEGs for LUAD patients. Our data might provide a new molecular target for LUAD treatment.
format Article
id doaj-art-cb2930bf0a264bf6ba8add71382280c3
institution Kabale University
issn 1471-2407
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-cb2930bf0a264bf6ba8add71382280c32025-01-19T12:26:59ZengBMCBMC Cancer1471-24072025-01-0125111810.1186/s12885-024-13409-wThe systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatmentYanchao Luan0Chao Liang1Qingsong Han2Xueqin Zhou3Na Yang4li Zhao5Hebei Chest HospitalHebei Provincial Lung Cancer Prevention and Treatment Research CenterHebei Provincial Lung Cancer Prevention and Treatment Research CenterHebei Provincial Lung Cancer Prevention and Treatment Research CenterHebei Provincial Lung Cancer Prevention and Treatment Research CenterHebei Provincial Lung Cancer Prevention and Treatment Research CenterAbstract Background Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD). Methods For the purpose of identifying butyrate metabolism-related differentially expressed genes (BMR-DEGs) in the TCGA-LUAD dataset, we introduced transcriptome data. This was followed by the implementation of the univariate Cox and LASSO analyses in order to construct a LUAD gene signature. We performed a comprehensive analysis of gene function enrichment between the two populations at risk, thoroughly examined their immune microenvironment characteristics, and assessed the effectiveness of immunotherapy. Finally, the function of CDKN3 in LUAD was verified by in vitro experiments. Results Through a comprehensive analysis of the TCGA-LUAD dataset, 51 significant BMR-DEGs were confirmed. Subsequently, five characteristic genes, CPS1, ABCC2, CDKN3, SLC2A1, and IGFBP1 were identified to create prognostic features for butyrate metabolism related outcomes in LUAD. Cox regression analysis determined that the pathological T stage, tumor stage, and RiskScore could serve as independent prognostic indicators. Analysis of the abundance of 22 immune infiltrating cells revealed that 15 immune cell types exhibited substantial differences and were strongly associated with risk ratings and prognosis. An important correlation exists between risk ratings and immunological checkpoints, which can be utilized to forecast the efficacy of treatment. In the high-risk group, there was an upregulation of the expression of PD-L2, PD-L1, and PD-1. Additionally, the risk score showed a positive correlation with TIDE and Exclusion score, while showing a negative correlation with Dysfunction score. Furthermore, the IC50 values for cisplatin, paclitaxel, and docetaxel were notably elevated in the high-risk group, indicating that these medications could potentially provide therapeutic advantages for this particular group. Finally, we determined that knockdown CDKN3 inhibited the proliferation and metastasis of LUAD cells. Conclusion We identify and validate a novel BMR-related prognostic signature comprising 5 DEGs for LUAD patients. Our data might provide a new molecular target for LUAD treatment.https://doi.org/10.1186/s12885-024-13409-wLung adenocarcinomaButyrate metabolismPrognostic signatureRisk subgroupsCDKN3
spellingShingle Yanchao Luan
Chao Liang
Qingsong Han
Xueqin Zhou
Na Yang
li Zhao
The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
BMC Cancer
Lung adenocarcinoma
Butyrate metabolism
Prognostic signature
Risk subgroups
CDKN3
title The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
title_full The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
title_fullStr The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
title_full_unstemmed The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
title_short The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
title_sort systematic analysis of genes related to butyrate metabolism suggests that cdkn3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
topic Lung adenocarcinoma
Butyrate metabolism
Prognostic signature
Risk subgroups
CDKN3
url https://doi.org/10.1186/s12885-024-13409-w
work_keys_str_mv AT yanchaoluan thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT chaoliang thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT qingsonghan thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT xueqinzhou thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT nayang thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT lizhao thesystematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT yanchaoluan systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT chaoliang systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT qingsonghan systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT xueqinzhou systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT nayang systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment
AT lizhao systematicanalysisofgenesrelatedtobutyratemetabolismsuggeststhatcdkn3couldserveasapromisingtherapeutictargetforlungadenocarcinomatreatment